A mouse model of orthotopic tumor xenografts derived from KLC primary cells was established, and then the mice were treated with the FDA-approved mTOR inhibitor everolimus (E) alone or in combination with the MEK inhibitor trametinib (E + T). This evidence concerns the gene MAP2K7 and neoplasm.